PrecisionLife appoints Colin Stubberfield as SVP Drug Discovery
PrecisionLife Limited has appointed Colin Stubberfield, Ph.D. as SVP Drug Discovery. He will be based at the company’s UK headquarters…
Pharmaceuticals, Biotechnology and Life Sciences
PrecisionLife Limited has appointed Colin Stubberfield, Ph.D. as SVP Drug Discovery. He will be based at the company’s UK headquarters…
Scientists from UK-headquartered AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyze the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2.
PrecisionLife is extending its relationships with some of the largest COVID-19 collaborative research projects as it offers free use of its analytics platform and support from its data and biomedical science teams in the fight against COVID19 coronavirus.